BACKGROUND: Cabozantinib targets tyrosine kinases including the hepatocyte growth factor receptor (MET) and vascular endothelial growth factor (VEGF) receptor 2, which are important drug targets in renal cell carcinoma (RCC).
PATIENTS AND METHODS: This single-arm open-label phase I trial evaluated the safety and tolerability of cabozantinib in heavily pretreated patients with metastatic clear cell RCC.
RESULTS: The study enrolled 25 RCC patients for whom standard therapy had failed. Patients received a median of two prior systemic agents, and most patients had previously received at least one VEGF pathway inhibiting therapy (22 patients [88%]). Common adverse events included fatigue, diarrhea, nausea, proteinuria, appetite decreased, palmar-plantar erythrodysesthesia, and vomiting. Partial response was reported in seven patients (28%). Median progression-free survival was 12.9 months, and median overall survival was 15.0 months.
CONCLUSION: Cabozantinib demonstrates preliminary anti-tumor activity and a safety profile similar to that seen with other multitargeted VEGFR tyrosine kinase inhibitors in advanced RCC patients. Further evaluation of cabozantinib in RCC is warranted.
Written by:
Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J, Kaelin WG, Dutcher JP. Are you the author?
Dana-Farber Cancer Institute and Harvard Medical School, Kidney Cancer Program, Boston; Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte; Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston; Clinical Development, Exelixis Inc., South San Francisco; St Luke's-Roosevelt Hospital Center, New York, USA.
Reference: Ann Oncol. 2014 May 14. pii: mdu184.
doi: 10.1093/annonc/mdu184
PubMed Abstract
PMID: 24827131
UroToday.com Renal Cancer Section
